on Biophytis (EPA:ALBPS)
Biophytis Engages in SCWD Congress and Hosts Obesity Investor Call
Biophytis SA, a biotechnology company specializing in age-related diseases, announced its participation in the 17th SCWD Congress in Washington, D.C., from December 6 to 8, 2024. The company will host an Obesity Investor Call focusing on GLP-1 RA weight loss therapy and its potential effects on muscle. Renowned experts, including Professors Roger Fielding, Marc André Cornier, and William Evans, will lead the discussion.
The session aims to provide insights into the clinical implications of muscle loss due to obesity treatments and explore potential therapeutic solutions. The CEO of Biophytis, Stanislas Veillet, will outline the company's strategy in this area. The event is scheduled for December 6 at 12:45 PM ET and will be accessible remotely for registered analysts and investors.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news